Repros Therapeutics Inc. (RPRX) Provides Clinical Update for Androxal® Phase 3 Program
9/13/2012 9:37:26 AM
THE WOODLANDS, Texas, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)today provided a clinical update of its Androxal® Phase 3 program.
Pivotal Phase 3 Studies
Repros has randomized the first subjects in ZA-301, the first of two pivotal studies. The study is being conducted at various US clinical sites.